Authors: Zaltzman, J McAlister, V Russell, D Halloran, P Landsberg, D Busque, S Shoker, A Boucher, A Shapiro, J Tchervenkov, J Peets, J

Citation: J. Zaltzman et al., Tacrolimus, MMF, steroid, and ALG immunotherapy for high immunological risk renal transplant recipients, TRANSPLAN P, 33(1-2), 2001, pp. 1044-1045

Authors: Busque, S Shoker, A Landsberg, D McAlister, V Halloran, P Shapiro, J Peets, J Schulz, M

Citation: S. Busque et al., Canadian multicentre trial of tacrolimus/azathioprine/steroids versus tacrolimus/mycophenolate mofetil/steroids versus neoral/mycophenolate mofetil/steroids in renal transplantation, TRANSPLAN P, 33(1-2), 2001, pp. 1266-1267

Authors: Chen, HF Peng, JZ Luo, HY Loubeau, M Wan, XC Xu, DS Qi, SJ Vu, MD Daloze, P Fitzsimmons, WE Bekersky, I Peets, J Sehgal, SN Wu, JP

Citation: Hf. Chen et al., Compromised kidney graft rejection response in vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus, TRANSPLANT, 69(8), 2000, pp. 1555-1561

Authors: Qi, SJ Xu, DS Peng, JZ Vu, MD Wu, JP Bekersky, I Fitzsimmons, WE Peets, J Sehgal, S Daloze, P Chen, HF

Citation: Sj. Qi et al., Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey, TRANSPLANT, 69(7), 2000, pp. 1275-1283